- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: DNA transcription.
Displaying page 1 of 1.
EudraCT Number: 2013-004747-23 | Sponsor Protocol Number: BPC01-001 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:Bionor Pharma ASA | |||||||||||||
Full Title: An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using Romidepsin, on the Viral Reservoir in Virologic... | |||||||||||||
Medical condition: HIV-infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003419-68 | Sponsor Protocol Number: HepBTer | Start Date*: 2020-12-18 | |||||||||||||||||||||||||||||||
Sponsor Name:Academic Medical Center (AMC) | |||||||||||||||||||||||||||||||||
Full Title: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients | |||||||||||||||||||||||||||||||||
Medical condition: Chronic hepatitis B infection | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003111-31 | Sponsor Protocol Number: 2007-1-18-20-6 | Start Date*: 2008-07-21 |
Sponsor Name:Charité - Universitaetsmedizin Berlin | ||
Full Title: Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative ... | ||
Medical condition: Post-operative immunological stimulation in severe immune suppression. The study population is made up of adult, which are able to give their inform consent by their own. The patients are undergoin... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000155-14 | Sponsor Protocol Number: V2.0 | Start Date*: 2013-12-13 |
Sponsor Name:Med. Universität Wien, Universitätsklinik für Innere Medizin II | ||
Full Title: In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD | ||
Medical condition: COPD | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001592-33 | Sponsor Protocol Number: 0204 | Start Date*: 2020-11-17 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Maternal Mental Health (MAMA) Study. Short time estrogen as a candidate strategy to prevent postpartum depression in a high-risk group | |||||||||||||
Medical condition: Perinatal depression with postpartum onset | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002927-39 | Sponsor Protocol Number: BOOST_TX/RESCUE_TX | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C... | ||
Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000533-22 | Sponsor Protocol Number: VX-950-TiDP24-C216 | Start Date*: 2008-11-14 | |||||||||||
Sponsor Name:Tibotec BVBA | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop... | |||||||||||||
Medical condition: Chronic genotype 1 Hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) SE (Completed) FR (Completed) AT (Completed) IT (Completed) GB (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000240-94 | Sponsor Protocol Number: CLEAR0001 | Start Date*: 2012-05-09 | ||||||||||||||||
Sponsor Name:Aarhus University Hospital | ||||||||||||||||||
Full Title: The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 from The Latent Reservoir (CLEAR) Study | ||||||||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV) Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000338-16 | Sponsor Protocol Number: 42847922MDD3002 | Start Date*: 2020-10-27 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld... | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) FI (Prematurely Ended) PL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003220-32 | Sponsor Protocol Number: EpicStudy | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:IRCCS MATERNO INFANTILE BURLO GAROFOLO | |||||||||||||
Full Title: Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel disease: a multicenter open-label randomized-control trial. | |||||||||||||
Medical condition: Pediatric Inflammatory Bowel Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000341-14 | Sponsor Protocol Number: 42847922MDD3005 | Start Date*: 2020-08-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ... | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) LT (Completed) LV (Completed) BE (Completed) BG (Completed) PL (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000337-40 | Sponsor Protocol Number: 42847922MDD3001 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld... | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004811-31 | Sponsor Protocol Number: GIMEMA MDS 0205 | Start Date*: 2006-05-16 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO | |||||||||||||
Full Title: An open label, phase II, non randomized, clinical trial of chemotherapy treatment with 5-Azacytidine plus valproic acid and eventually atra for patients diagnosed with Intermediate II and high risk... | |||||||||||||
Medical condition: Intermediate II and high risk Myelodysplastic syndrome MDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002139-94 | Sponsor Protocol Number: IPH1101-203 | Start Date*: 2007-06-19 | |||||||||||
Sponsor Name:Innate Pharma | |||||||||||||
Full Title: Multiple dose Phase II study of IPH1101 in monotherapy or associated with a low dose of IL2 (2MIU) in non previously treated hepatitis C patients | |||||||||||||
Medical condition: Non previously treated Hepatitis C patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005238-23 | Sponsor Protocol Number: MCA-896 | Start Date*: 2016-10-18 | ||||||||||||||||
Sponsor Name:Rockefeller University | ||||||||||||||||||
Full Title: A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP) | ||||||||||||||||||
Medical condition: HIV infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003951-23 | Sponsor Protocol Number: AG-221-AML-005 | Start Date*: 2016-07-08 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 P... | |||||||||||||
Medical condition: Newly diagnosed acute myeloid leukemia (AML) habouring an isocitrate dehydrogenase 1 (IDH1) or an isocitrate dehydrogenase 2 (IDH2) mutation, respectively, who are not candidates to receive intensi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PT (Completed) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
